Overview

Topical IL-1-Ra for Treatment of Corneal Neovascularization

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Reza Dana, MD
Treatments:
Interleukin 1 Receptor Antagonist Protein